Market News AIOpen the app

UBS kept a 'Neutral' rating on Novartis and set a price target of 130 Swiss francs after meeting with its leaders.

OpinionRead the original at finanzen.ch
Neutral

Novartis management voiced confidence about plans through 2031, but UBS said the targets are largely in line with market expectations. With no new sales or drug results, the meeting does not change the company's prospects.

NVS · Novartis AG

AI read · Neutral

The AI's read

That leaves little new evidence to change how Novartis is viewed. Management sounded confident about plans through 2031, but its targets are largely in line with market expectations. The meeting reported no new sales, profit, or drug-development results.

Get alerts for NVS

Follow Novartis AG (NVS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for NVS
Free on the App Store and Google Play, or on the web.